Metabolic Mechanism of Delamanid, a New Anti-Tuberculosis Drug, in Human Plasma

Drug Metabolism and Disposition - United States
doi 10.1124/dmd.115.064550
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Related search

A Clinical Case of Effective Treatment of Extensive Drug Resistance Tuberculosis With New Anti-Tuberculosis Drugs

Tuberkulëz i bolezni lëgkikh
PulmonaryInfectious DiseasesRespiratory Medicine
2017English

Delamanid and Bedaquiline Resistance inMycobacterium tuberculosisAncestral Beijing Genotype Causing Extensively Drug-Resistant Tuberculosis in a Tibetan Refugee

American Journal of Respiratory and Critical Care Medicine
PulmonaryCritical CareRespiratory MedicineIntensive Care Medicine
2016English

Final Treatment Outcomes of Multidrug- And Extensively Drug-Resistant Tuberculosis Patients in Latvia Receiving Delamanid-Containing Regimens

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2017English

Drug-Resistant Tuberculosis and Group 5 Anti-Tuberculosis Drugs

Archives of Pediatric Infectious Diseases
Child HealthInfectious DiseasesPediatricsPerinatology
2015English

Mechanism of Interaction of Anti-Microbial Drug Cefdinir With Human Serum Albumin

Journal of Pharmacology and Toxicology
ToxicologyPharmaceuticsPharmacology
2006English

Mechanism of Analgesic Action of Y-23023, a New Non-Steroidal Anti-Inflammatory Drug.

Folia Pharmacologica Japonica
Pharmacology
1995English

Treatment Outcomes of Regimens Containing Delamanid Within Therapy of Multiple and Extensive Drug Resistant Tuberculosis in the Russian Federation

Tuberkulëz i bolezni lëgkikh
PulmonaryInfectious DiseasesRespiratory Medicine
2019English

4th National Anti-Tuberculosis Drug Resistance Survey in Kenya

J. of Health Science
2017English

Incidence of Adverse Drug Reactions in Patients Taking Anti-Tuberculosis Treatment

International Journal of Advances in Medicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy